Killing bacteria by silencing genes may be alternative to antibiotics

June 6, 2018 by Katie Bohn, Pennsylvania State University
C. difficile
This photograph depicts Clostridium difficile colonies after 48hrs growth on a blood agar plate; Magnified 4.8X. C. difficile, an anaerobic gram-positive rod, is the most frequently identified cause of antibiotic-associated diarrhea (AAD). It accounts for approximately 15-25% of all episodes of AAD. Credit: CDC

A new approach to killing C. difficile that silences key bacterial genes while sparing other bacteria may provide a new way to treat the most common hospital-acquired bacterial infection in the United States, according to researchers.

While conventional treat bacterial infections, they can also cause a condition in the colon called C. difficile infection, due to the drug killing both good and bad bacteria in the gut.

In a lab, researchers created three new antibiotics that kill C. difficile by preventing the expression of bacterial genes that are important for its survival. This approach—called antisense therapy—allows the drug to kill only C. difficile, unlike many antibiotics that kill multiple forms of bacteria.

"We were able to show that these drugs can zero in on and kill C. difficile bacteria while leaving other bacteria alone," said Arun Sharma, associate professor of pharmacology, Penn State College of Medicine. "We're still working to refine these drugs and make them even better, with the eventual goal of testing them clinically."

David Stewart, an associate professor of surgery at the University of Arizona who along with Sharma is a co-principal investigator on this study, said the drug works in a completely different manner than the antibiotics currently used.

"These drugs are organism specific, meaning that they target only one kind of bacteria, kind of like smart antibiotics," Stewart said. "They're precise. And that's especially important with C. difficile infections because this bacteria is uniquely, selectively advantaged to exploit ecological disturbances in the human gut."

While C. difficile is normally present in the gut, other "good" bacteria are also present, and all these bacteria contribute to a person's microbiome. When a person's microbiome is healthy and balanced, it keeps bad bacteria like C. difficile under control.

But if a patient takes an antibiotic for another condition, the antibiotic kills many different types of bacteria, including the good ones keeping C. difficile under control. This allows C. difficile to thrive, causing an that can result in severe gastrointestinal symptoms. Since antibiotics can contribute to C. difficile infections, the researchers said a new, alternative treatment for these infections is desirable.

"Ideally, a treatment for C. difficile would have no effect on other bacteria," Stewart said.

The researchers, who recently published their findings in the Journal of Antibiotics, said that while most antibiotics lack organismal specificity—the ability to target just one type of organism—antisense treatments show great potential for being able to target only specific bacteria.

"Our antisense antibiotics contain genetic material which is complementary to bacterial genetic material, so we designed our genetic material to target specific genes in C. difficile," Stewart said. "And when our genetic material binds to the bacterial genetic material, it prevents the expression of . And that can cause C. difficile to die."

The drug tested in the study consisted of two components: the antisense compound that targeted the in C. difficile—referred to as an antisense oligonucleotide (ASO)—and a carrier compound that transported the ASO into the bacteria, referred to by the research team as a CAB. The researchers tested three versions of the drug, each with a different version of CAB.

The researchers tested each compound to see how much of the drug was required to kill C. difficile bacteria, whether it was toxic or not to human colon cells, and whether it also harmed other bacteria normally found in the gut—like E. coli.

"Ultimately, we wanted these compounds to deliver the drug into the C. difficile bacteria without hurting other bacteria or the patient," Sharma said. "After testing these three, we found that one carrier in particular—CYDE-21—was the best at delivering an effective dose of the into the bacteria."

In the future, the researchers said they will conduct further studies to continue to refine the carriers to increase their capacity and minimize their effect on other and human cells.

"In this study, as a first effort, the carrier is pretty good, and we'd like to do even better," Stewart said. "It has minimal antibacterial activity, minimal toxicity and it's an effective carrier of our cargo. So what we're working on now is modifying our carriers for future testing in preparation for animal studies."

Explore further: Metabolite therapy proves effective in treating C. difficile in mice

Related Stories

Metabolite therapy proves effective in treating C. difficile in mice

March 20, 2018
A team of UCLA researchers found that a metabolite therapy was effective in mice for treating a serious infection of the colon known as Clostridium difficile infection, or C. difficile.

Bacteriophages battle superbugs

July 18, 2013
IFR microbiologists are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals.

Molecular weapon targets bad bacteria

January 12, 2018
Instead of prescribing a broad-spectrum antibiotic, like a tiny nuclear missile that indiscriminately kills both bad and good bacteria, Greg Gloor is working on developing a targeted molecular weapon that will combat only ...

Research opens possibility of reducing risk of gut bacterial infections with next-generation probiotics

August 9, 2017
A team of researchers is exploring the possibility that next-generation probiotics – live bacteria that are good for your health – would reduce the risk of infection with the bacterium Clostridium difficile. In laboratory-grown ...

University of Minnesota startup to treat challenging bacterial infection

May 16, 2012
A live biological preparation developed by University of Minnesota researchers could put a stop to an increasingly prevalent, and sometimes deadly, infection caused by the bacterium Clostridium difficile. CIPAC Limited, based ...

Recommended for you

Study shows how MERS coronavirus evolves to infect different species

August 14, 2018
In the past 15 years, two outbreaks of severe respiratory disease were caused by coronaviruses transmitted from animals to humans. In 2003, SARS-CoV (severe acute respiratory syndrome coronavirus) spread from civets to infect ...

Inching closer to a soft spot in isoniazid-resistant tuberculosis

August 14, 2018
Antibiotic-resistant tuberculosis is a public health threat. TB and other bacteria become resistant to antibiotics by evolving genetic changes over time, which they can do quite quickly because bacterial lifecycles are short. ...

How long is an Ebola survivor contagious? One case is causing scientists to rethink the answer.

August 14, 2018
Surviving Ebola isn't like getting over the flu.

Why do women get more migraines?

August 14, 2018
Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect ...

Link between common 'harmless' virus and cardiovascular damage

August 13, 2018
Researchers from Brighton and Sussex Medical School (BSMS) have found an unexpectedly close link between a herpes virus and the occurrence of immune cells damaging cardiovascular tissue.

Rotavirus vaccine cuts infant diarrhoea deaths by a third in Malawi

August 11, 2018
A major new study has shown that rotavirus vaccination reduced infant diarrhoea deaths by 34% in rural Malawi, a region with high levels of child deaths.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.